Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Medical Research
Published in: European Journal of Medical Research 1/2023

Open Access 01-12-2023 | Cervical Cancer | Review

MicroRNAs as the critical regulators of Forkhead box protein family during gynecological and breast tumor progression and metastasis

Authors: Negin Taghehchian, Malihe Lotfi, Amir Sadra Zangouei, Iman Akhlaghipour, Meysam Moghbeli

Published in: European Journal of Medical Research | Issue 1/2023

Login to get access

Abstract

Gynecological and breast tumors are one of the main causes of cancer-related mortalities among women. Despite recent advances in diagnostic and therapeutic methods, tumor relapse is observed in a high percentage of these patients due to the treatment failure. Late diagnosis in advanced tumor stages is one of the main reasons for the treatment failure and recurrence in these tumors. Therefore, it is necessary to assess the molecular mechanisms involved in progression of these tumors to introduce the efficient early diagnostic markers. Fokhead Box (FOX) is a family of transcription factors with a key role in regulation of a wide variety of cellular mechanisms. Deregulation of FOX proteins has been observed in different cancers. MicroRNAs (miRNAs) as a group of non-coding RNAs have important roles in post-transcriptional regulation of the genes involved in cellular mechanisms. They are also the non-invasive diagnostic markers due to their high stability in body fluids. Considering the importance of FOX proteins in the progression of breast and gynecological tumors, we investigated the role of miRNAs in regulation of the FOX proteins in these tumors. MicroRNAs were mainly involved in progression of these tumors through FOXM, FOXP, and FOXO. The present review paves the way to suggest a non-invasive diagnostic panel marker based on the miRNAs/FOX axis in breast and gynecological cancers.
Literature
1.
Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed
2.
Louwman MWJ, et al. Uncommon breast tumors in perspective: incidence, treatment and survival in the Netherlands. Int J Cancer. 2007;121(1):127–35.PubMed
3.
Rosen PP. Rosen’s breast pathology. Philadelphia: Lippincott Williams & Wilkins; 2001.
4.
Tavassoli FA. Pathology and genetics of tumours of the breast and female genital organs. Geneva: World Health Organization Classification of Tumours; 2003.
5.
Minami K, et al. Lysophosphatidic acid receptor-2 (LPA2)-mediated signaling enhances chemoresistance in melanoma cells treated with anticancer drugs. Mol Cell Biochem. 2020;469(1–2):89–95.PubMed
6.
Moghbeli M, et al. ErbB1 and ErbB3 co-over expression as a prognostic factor in gastric cancer. Biol Res. 2019;52(1):2.PubMedPubMedCentral
7.
Li X, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008;100(9):672–9.PubMed
8.
Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol. 2005;205(2):275–92.PubMed
9.
Buckley AM, et al. Targeting hallmarks of cancer to enhance radiosensitivity in gastrointestinal cancers. Nat Rev Gastroenterol Hepatol. 2020;17(5):298–313.PubMed
10.
Torres-Collado AX, Knott J, Jazirehi AR. Reversal of resistance in targeted therapy of metastatic melanoma: lessons learned from vemurafenib (BRAF(V600E)-specific inhibitor). Cancers. 2018;10(6):157.PubMedPubMedCentral
11.
12.
Maeda H, Khatami M. Analyses of repeated failures in cancer therapy for solid tumors: poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs. Clin Transl Med. 2018;7(1):11.PubMedPubMedCentral
13.
DeSantis C, et al. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64(1):52–62.PubMed
14.
Spurdle AB, et al. Genome-wide association study identifies a common variant associated with risk of endometrial cancer. Nat Genet. 2011;43(5):451–4.PubMedPubMedCentral
15.
Randall ME, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2006;24(1):36–44.PubMed
16.
Oronsky B, et al. A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer. Med Oncol. 2017;34(6):103.PubMed
17.
Nezhat FR, et al. New insights in the pathophysiology of ovarian cancer and implications for screening and prevention. Am J Obstet Gynecol. 2015;213(3):262–7.PubMed
18.
Rosen B, et al. The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer. Gynecol Oncol. 2014;134(3):462–7.PubMed
19.
Lokadasan R, et al. Targeted agents in epithelial ovarian cancer: review on emerging therapies and future developments. Ecancermedicalscience. 2016;10:626.PubMedPubMedCentral
20.
Kumar L, Gupta S. Integrating chemotherapy in the management of cervical cancer: a critical appraisal. Oncology. 2016;91(Suppl 1):8–17.PubMed
21.
Myatt SS, Lam EW. The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer. 2007;7(11):847–59.PubMed
22.
Dai S, et al. Structural basis for DNA recognition by FOXG1 and the characterization of disease-causing FOXG1 mutations. J Mol Biol. 2020;432(23):6146–56.PubMed
23.
Lai E, et al. Hepatocyte nuclear factor 3/fork head or “winged helix” proteins: a family of transcription factors of diverse biologic function. Proc Natl Acad Sci. 1993;90(22):10421–3.PubMedPubMedCentral
24.
Benayoun BA, Caburet S, Veitia RA. Forkhead transcription factors: key players in health and disease. Trends Genet. 2011;27(6):224–32.PubMed
25.
Clark KL, et al. Co-crystal structure of the HNF-3/fork head DNA-recognition motif resembles histone H5. Nature. 1993;364(6436):412–20.PubMed
26.
Obsil T, Obsilova V. Structure/function relationships underlying regulation of FOXO transcription factors. Oncogene. 2008;27(16):2263–75.PubMed
27.
Cirillo LA, Zaret KS. Specific interactions of the wing domains of FOXA1 transcription factor with DNA. J Mol Biol. 2007;366(3):720–4.PubMed
28.
Romanelli MG, Lorenzi P, Morandi C. Nuclear localization domains in human thyroid transcription factor 2. Biochim Biophys Acta (BBA) Mol Cell Res. 2003;1643(1–3):55–64.
29.
Hancock WW, Özkaynak E. Three distinct domains contribute to nuclear transport of murine Foxp3. PLoS ONE. 2009;4(11):e7890.PubMedPubMedCentral
30.
Wang L, et al. Forkhead box protein C1 promotes cell proliferation and invasion in human cervical cancer. Mol Med Rep. 2018;17(3):4392–8.PubMedPubMedCentral
31.
Gu F, et al. Effects of forkhead box protein A1 on cell proliferation regulating and EMT of cervical carcinoma. Eur Rev Med Pharmacol Sci. 2018;22(21):7189–96.PubMed
32.
Sahoo SS, et al. FOXA2 suppresses endometrial carcinogenesis and epithelial-mesenchymal transition by regulating enhancer activity. J Clin Invest. 2022;132(12):e157574.PubMedPubMedCentral
33.
Li C, et al. Forkhead box protein C2 (FOXC2) promotes the resistance of human ovarian cancer cells to cisplatin in vitro and in vivo. Cell Physiol Biochem. 2016;39(1):242–52.PubMed
34.
O’Regan RM, Nahta R. Targeting forkhead box M1 transcription factor in breast cancer. Biochem Pharmacol. 2018;154:407–13.PubMedPubMedCentral
35.
Lu J, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834–8.PubMed
36.
Maharati A, et al. MicroRNAs as the critical regulators of tyrosine kinase inhibitors resistance in lung tumor cells. Cell Commun Signal. 2022;20(1):27.PubMedPubMedCentral
37.
38.
Lee Y, et al. The nuclear RNase III Drosha initiates microRNA processing. Nature. 2003;425(6956):415–9.PubMed
39.
Lund E, et al. Nuclear export of microRNA precursors. Science. 2004;303(5654):95–8.PubMed
40.
Yi R, et al. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev. 2003;17(24):3011–6.PubMedPubMedCentral
41.
Weng Y-T, Chang Y-M, Chern Y. The impact of dysregulated microRNA biogenesis machinery and microRNA sorting on neurodegenerative diseases. Int J Mol Sci. 2023;24(4):3443.PubMedPubMedCentral
42.
Moghbeli M. MicroRNAs as the critical regulators of Cisplatin resistance in ovarian cancer cells. J Ovarian Res. 2021;14(1):127.PubMedPubMedCentral
43.
Zangouei AS, Alimardani M, Moghbeli M. MicroRNAs as the critical regulators of Doxorubicin resistance in breast tumor cells. Cancer Cell Int. 2021;21(1):213.PubMedPubMedCentral
44.
Zangouei AS, et al. Non coding RNAs as the critical factors in chemo resistance of bladder tumor cells. Diagn Pathol. 2020;15(1):136.PubMedPubMedCentral
45.
Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics: a comprehensive review. EMBO Mol Med. 2012;4(3):143–59.PubMedPubMedCentral
46.
Moghbeli M, et al. Molecular mechanisms of the microRNA-132 during tumor progressions. Cancer Cell Int. 2021;21(1):439.PubMedPubMedCentral
47.
Chen X, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18(10):997–1006.PubMed
48.
Mitchell PS, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008;105(30):10513–8.PubMedPubMedCentral
49.
Michael A, et al. Exosomes from human saliva as a source of microRNA biomarkers. Oral Dis. 2010;16(1):34–8.PubMed
50.
Moghbeli M. Molecular interactions of miR-338 during tumor progression and metastasis. Cell Mol Biol Lett. 2021;26(1):13.PubMedPubMedCentral
51.
Hou T, et al. MicroRNA-196a promotes cervical cancer proliferation through the regulation of FOXO1 and p27Kip1. Br J Cancer. 2014;110(5):1260–8.PubMedPubMedCentral
52.
Lin H, et al. Unregulated miR-96 induces cell proliferation in human breast cancer by downregulating transcriptional factor FOXO3a. PLoS ONE. 2010;5(12):e15797.PubMedPubMedCentral
53.
Jägle S, et al. SNAIL1-mediated downregulation of FOXA proteins facilitates the inactivation of transcriptional enhancer elements at key epithelial genes in colorectal cancer cells. PLoS Genet. 2017;13(11):e1007109.PubMedPubMedCentral
54.
Friedman J, Kaestner KH. The Foxa family of transcription factors in development and metabolism. Cell Mol Life Sci. 2006;63:2317–28.PubMed
55.
Shen S-Q, et al. miR-204 regulates the biological behavior of breast cancer MCF-7 cells by directly targeting FOXA1. Oncol Rep. 2017;38(1):368–76.PubMed
56.
Salem M, et al. miR-590-3p promotes ovarian cancer growth and metastasis via a novel FOXA2–versican pathway. Can Res. 2018;78(15):4175–90.
57.
Cui YM, et al. FOXC2 promotes colorectal cancer metastasis by directly targeting MET. Oncogene. 2015;34(33):4379–90.PubMed
58.
Song L, et al. FOXC2 positively regulates YAP signaling and promotes the glycolysis of nasopharyngeal carcinoma. Exp Cell Res. 2017;357(1):17–24.PubMed
59.
Wang T, et al. Emerging roles and mechanisms of FOXC2 in cancer. Clin Chim Acta. 2018;479:84–93.PubMed
60.
Amin NM, Shi H, Liu J. The FoxF/FoxC factor LET-381 directly regulates both cell fate specification and cell differentiation in C. elegans mesoderm development. Development. 2010;137(9):1451–60.PubMedPubMedCentral
61.
Fatima A, et al. Foxc1 and Foxc2 deletion causes abnormal lymphangiogenesis and correlates with ERK hyperactivation. J Clin Investig. 2016;126(7):2437–51.PubMedPubMedCentral
62.
Norrmén C, et al. FOXC2 controls formation and maturation of lymphatic collecting vessels through cooperation with NFATc1. J Cell Biol. 2009;185(3):439–57.PubMedPubMedCentral
63.
Xu Y-Y, et al. MicroRNA-495 downregulates FOXC1 expression to suppress cell growth and migration in endometrial cancer. Tumor Biol. 2016;37(1):239–51.
64.
Sherman JH, et al. Foxd4 is essential for establishing neural cell fate and for neuronal differentiation. Genesis. 2017;55(6):e23031.
65.
66.
Quintero-Ronderos P, Laissue P. The multisystemic functions of FOXD1 in development and disease. J Mol Med. 2018;96(8):725–39.PubMed
67.
Yan JH, et al. FOXD3 suppresses tumor growth and angiogenesis in non-small cell lung cancer. Biochem Biophys Res Commun. 2015;466(1):111–6.PubMed
68.
Chu TL, et al. FoxD3 deficiency promotes breast cancer progression by induction of epithelial-mesenchymal transition. Biochem Biophys Res Commun. 2014;446(2):580–4.PubMed
69.
Li D, et al. FOXD3 is a novel tumor suppressor that affects growth, invasion, metastasis and angiogenesis of neuroblastoma. Oncotarget. 2013;4(11):2021–44.PubMedPubMedCentral
70.
Rahmani Z, Mojarrad M, Moghbeli M. Long non-coding RNAs as the critical factors during tumor progressions among Iranian population: an overview. Cell Biosci. 2020;10:6.PubMedPubMedCentral
71.
Hamidi AA, et al. Long non-coding RNAs as the critical regulators of epithelial mesenchymal transition in colorectal tumor cells: an overview. Cancer Cell Int. 2022;22(1):71.PubMedPubMedCentral
72.
Zhang D, Zhang Y, Sun X. LINC01133 promotes the progression of cervical cancer via regulating miR-30a-5p/FOXD1. Asia Pac J Clin Oncol. 2021;17(3):253–63.PubMed
73.
Scott RW, Olson MF. LIM kinases: function, regulation and association with human disease. J Mol Med. 2007;85(6):555–68.PubMed
74.
Zhou Y, et al. Maternal exposure to Nanoparticulate titanium dioxide causes inhibition of hippocampal development involving dysfunction of the rho/NMDAR signaling pathway in offspring. J Biomed Nanotechnol. 2019;15(4):839–47.PubMed
75.
Yang X, et al. FOXD3-AS1/miR-128-3p/LIMK1 axis regulates cervical cancer progression. Oncol Rep. 2021;45(5):1–12.
76.
Zhang X, et al. MicroRNA-182 promotes proliferation and metastasis by targeting FOXF2 in triple-negative breast cancer. Oncol Lett. 2017;14(4):4805–11.PubMedPubMedCentral
77.
Wang A, et al. LncRNA ADAMTS9-AS2 regulates ovarian cancer progression by targeting miR-182-5p/FOXF2 signaling pathway. Int J Biol Macromol. 2018;120:1705–13.PubMed
78.
79.
Sun N, Taguchi A, Hanash S. Switching roles of TGF-β in cancer development: implications for therapeutic target and biomarker studies. J Clin Med. 2016;5(12):109.PubMedPubMedCentral
80.
Neel J-C, Humbert L, Lebrun J-J. The dual role of TGFβ in human cancer: from tumor suppression to cancer metastasis. Int Sch Res Not. 2012;2012:1–28.
81.
Leight JL, et al. Matrix rigidity regulates a switch between TGF-β1–induced apoptosis and epithelial–mesenchymal transition. Mol Biol Cell. 2012;23(5):781–91.PubMedPubMedCentral
82.
Hou P-S, et al. Transcription and beyond: delineating FOXG1 function in cortical development and disorders. Front Cell Neurosci. 2020;14:35.PubMedPubMedCentral
83.
Hannenhalli S, Kaestner KH. The evolution of Fox genes and their role in development and disease. Nat Rev Genet. 2009;10(4):233–40.PubMedPubMedCentral
84.
Chan D, et al. Overexpression of FOXG1 contributes to TGF-β resistance through inhibition of p21WAF1/CIP1 expression in ovarian cancer. Br J Cancer. 2009;101(8):1433–43.PubMedPubMedCentral
85.
Adesina AM, et al. FOXG1 dysregulation is a frequent event in medulloblastoma. J Neurooncol. 2007;85(2):111–22.PubMed
86.
Zeng F, et al. MiR-200b promotes the cell proliferation and metastasis of cervical cancer by inhibiting FOXG1. Biomed Pharmacother. 2016;79:294–301.PubMed
87.
Liu Y, et al. FOXK transcription factors: regulation and critical role in cancer. Cancer Lett. 2019;458:1–12.PubMed
88.
Gao F, Tian J. FOXK1, regulated by miR-365-3p, promotes cell growth and EMT indicates unfavorable prognosis in breast cancer. Onco Targets Ther. 2020;13:623.PubMedPubMedCentral
89.
Bella L, et al. FOXM1: a key oncofoetal transcription factor in health and disease. Semin Cancer Biol. 2014;29:32–9.PubMed
90.
Li L, et al. Prognostic value of FOXM1 in solid tumors: a systematic review and meta-analysis. Oncotarget. 2017;8(19):32298–308.PubMedPubMedCentral
91.
92.
Schmadeka R, Harmon BE, Singh M. Triple-negative breast carcinoma: current and emerging concepts. Am J Clin Pathol. 2014;141(4):462–77.PubMed
93.
Cadoo K, Fornier M, Morris P. Biological subtypes of breast cancer: current concepts and implications for recurrence patterns. Q J Nucl Med Mol Imaging. 2013;57(4):312–21.PubMed
94.
Carey LA, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13(8):2329–34.PubMed
95.
Schüller U, et al. Forkhead transcription factor FoxM1 regulates mitotic entry and prevents spindle defects in cerebellar granule neuron precursors. Mol Cell Biol. 2007;27(23):8259–70.PubMedPubMedCentral
96.
Wang I-C, et al. Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Mol Cell Biol. 2005;25(24):10875–94.PubMedPubMedCentral
97.
Wierstra I. The transcription factor FOXM1 (Forkhead box M1): proliferation-specific expression, transcription factor function, target genes, mouse models, and normal biological roles. Adv Cancer Res. 2013;118:97–398.PubMed
98.
Wang X, et al. The Forkhead Box m1b transcription factor is essential for hepatocyte DNA replication and mitosis during mouse liver regeneration. Proc Natl Acad Sci. 2002;99(26):16881–6.PubMedPubMedCentral
99.
Wang X, et al. Increased hepatic Forkhead Box M1B (FoxM1B) levels in old-aged mice stimulated liver regeneration through diminished p27Kip1 protein levels and increased Cdc25B expression. J Biol Chem. 2002;277(46):44310–6.PubMed
100.
Wang Q, et al. Targeted interfering DEP domain containing 1 protein induces apoptosis in A549 lung adenocarcinoma cells through the NF-κB signaling pathway. Onco Targets Ther. 2017;10:4443.PubMedPubMedCentral
101.
Zhang L, et al. DEPDC1, negatively regulated by miR-26b, facilitates cell proliferation via the up-regulation of FOXM1 expression in TNBC. Cancer Lett. 2019;442:242–51.PubMed
102.
Kenney JW, et al. Eukaryotic elongation factor 2 kinase, an unusual enzyme with multiple roles. Adv Biol Regul. 2014;55:15–27.PubMed
103.
104.
Moore CE, et al. Elongation factor 2 kinase promotes cell survival by inhibiting protein synthesis without inducing autophagy. Cell Signal. 2016;28(4):284–93.PubMedPubMedCentral
105.
Bayraktar R, et al. Dual suppressive effect of miR-34a on the FOXM1/eEF2-kinase axis regulates triple-negative breast cancer growth and invasion. Clin Cancer Res. 2018;24(17):4225–41.PubMed
106.
Shi M, Cui J, Xie K. Signaling of miRNAs-FOXM1 in cancer and potential targeted therapy. Curr Drug Targets. 2013;14(10):1192–202.PubMedPubMedCentral
107.
Yuan F, Wang W. MicroRNA-802 suppresses breast cancer proliferation through downregulation of FoxM1. Mol Med Rep. 2015;12(3):4647–51.PubMed
108.
Li X-R, et al. miR-342-3p suppresses proliferation, migration and invasion by targeting FOXM1 in human cervical cancer. FEBS Lett. 2014;588(17):3298–307.PubMed
109.
Liang L, Zheng YW, Wang YL. miR-4429 Regulates the proliferation, migration, invasion, and epithelial-mesenchymal transition of cervical cancer by targeting FOXM1. Cancer Manag Res. 2020;12:5301.PubMedPubMedCentral
110.
Li M, et al. Circular PVT1 regulates cell proliferation and invasion via miR-149-5p/FOXM1 axis in ovarian cancer. J Cancer. 2021;12(2):611.PubMedPubMedCentral
111.
Hong H, et al. The novel circCLK3/miR-320a/FoxM1 axis promotes cervical cancer progression. Cell Death Dis. 2019;10(12):1–19.
112.
Gao F, et al. LncRNA SBF2-AS1 promotes the progression of cervical cancer by regulating miR-361-5p/FOXM1 axis. Artif Cells Nanomed Biotechnol. 2019;47(1):776–82.PubMed
113.
Dong G, et al. FBXL19-AS1 promotes cell proliferation and inhibits cell apoptosis via miR-876-5p/FOXM1 axis in breast cancer. Acta Biochim Biophys Sin. 2019;51(11):1106–13.PubMed
114.
Tan X, et al. miR-671-5p inhibits epithelial-to-mesenchymal transition by downregulating FOXM1 expression in breast cancer. Oncotarget. 2016;7(1):293.PubMed
115.
He S, et al. MiR-216b inhibits cell proliferation by targeting FOXM1 in cervical cancer cells and is associated with better prognosis. BMC Cancer. 2017;17(1):1–12.
116.
Hu Q, et al. miR-197 is downregulated in cervical carcinogenesis and suppresses cell proliferation and invasion through targeting forkhead box M1. Oncol Lett. 2018;15(6):10063–9.PubMedPubMedCentral
117.
Shi C, Zhang Z. MicroRNA-320 suppresses cervical cancer cell viability, migration and invasion via directly targeting FOXM1. Oncol Lett. 2017;14(3):3809–16.PubMedPubMedCentral
118.
Xia N, et al. MiR-374b reduces cell proliferation and cell invasion of cervical cancer through regulating FOXM1. Eur Rev Med Pharmacol Sci. 2019;23(2):513–21.PubMed
119.
Dai S, et al. Long non-coding RNA WT1-AS inhibits cell aggressiveness via miR-203a-5p/FOXN2 axis and is associated with prognosis in cervical cancer. Eur Rev Med Pharmacol Sci. 2019;23(2):486–95.PubMed
120.
Huang H, Tindall DJ. Dynamic FoxO transcription factors. J Cell Sci. 2007;120(15):2479–87.PubMed
121.
Kousteni S. FoxO1: a molecule for all seasons. J Bone Miner Res. 2011;26(5):912–7.PubMed
122.
Navaei ZN, et al. PI3K/AKT signaling pathway as a critical regulator of Cisplatin response in tumor cells. Oncol Res. 2021;29(4):235–50.PubMed
123.
Xu H, et al. Inhibition of microRNA-181a may suppress proliferation and invasion and promote apoptosis of cervical cancer cells through the PTEN/Akt/FOXO1 pathway. J Physiol Biochem. 2016;72(4):721–32.PubMed
124.
Xu Y, et al. Down-regulation of microRNA-135b inhibited growth of cervical cancer cells by targeting FOXO1. Int J Clin Exp Pathol. 2015;8(9):10294.PubMedPubMedCentral
125.
Yang L, et al. miR-96 enhances the proliferation of cervical cancer cells by targeting FOXO1. Pathol Res Pract. 2020;216(4):152854.PubMed
126.
Peralta-Arrieta I, et al. DNMT3B modulates the expression of cancer-related genes and downregulates the expression of the gene VAV3 via methylation. Am J Cancer Res. 2017;7(1):77.PubMedPubMedCentral
127.
Rahman MM, et al. DNA methyltransferases 1, 3a, and 3b overexpression and clinical significance in gastroenteropancreatic neuroendocrine tumors. Hum Pathol. 2010;41(8):1069–78.PubMed
128.
Li W, et al. miR-29c plays a suppressive role in breast cancer by targeting the TIMP3/STAT1/FOXO1 pathway. Clin Epigenetics. 2018;10(1):1–14.
129.
Liu D-Z, et al. MicroRNA-9 promotes the proliferation, migration, and invasion of breast cancer cells via down-regulating FOXO1. Clin Transl Oncol. 2017;19(9):1133–40.PubMed
130.
Oh BY, et al. Twist1-induced epithelial-mesenchymal transition according to microsatellite instability status in colon cancer cells. Oncotarget. 2016;7(35):57066.PubMedPubMedCentral
131.
Croset M, et al. TWIST1 expression in breast cancer cells facilitates bone metastasis formation. J Bone Miner Res. 2014;29(8):1886–99.PubMed
132.
Jin L, et al. FOXO3a inhibits the EMT and metastasis of breast cancer by regulating TWIST-1 mediated miR-10b/CADM2 axis. Transl Oncol. 2021;14(7):101096.PubMedPubMedCentral
133.
Chen J, Chen H, Pan L. SIRT1 and gynecological malignancies. Oncol Rep. 2021;45(4):1–11.
134.
135.
Alves-Fernandes DK, Jasiulionis MG. The role of SIRT1 on DNA damage response and epigenetic alterations in cancer. Int J Mol Sci. 2019;20(13):3153.PubMedPubMedCentral
136.
Xia X, et al. MicroRNA-506-3p inhibits proliferation and promotes apoptosis in ovarian cancer cell via targeting SIRT1/AKT/FOXO3a signaling pathway. Neoplasma. 2020;67(2):344–53.PubMed
137.
Sang Y, et al. circRNA_0025202 regulates tamoxifen sensitivity and tumor progression via regulating the miR-182-5p/FOXO3a axis in breast cancer. Mol Ther. 2019;27(9):1638–52.PubMedPubMedCentral
138.
Zhu D, et al. Overexpression of miR-148a inhibits viability and invasion of ovarian cancer OVCAR3 cells by targeting FOXO3. Oncol Lett. 2019;18(1):402–10.PubMedPubMedCentral
139.
Li J, et al. microRNA-150 promotes cervical cancer cell growth and survival by targeting FOXO4. BMC Mol Biol. 2015;16(1):1–9.
140.
Kim J-H, et al. Molecular networks of FOXP family: dual biologic functions, interplay with other molecules and clinical implications in cancer progression. Mol Cancer. 2019;18(1):1–19.
141.
Carvalho MI, et al. Intratumoral FoxP3 expression is associated with angiogenesis and prognosis in malignant canine mammary tumors. Vet Immunol Immunopathol. 2016;178:1–9.PubMed
142.
Chiu YC, et al. Foxp2 regulates neuronal differentiation and neuronal subtype specification. Dev Neurobiol. 2014;74(7):723–38.PubMed
143.
Tanida I, et al. Lysosomal turnover, but not a cellular level, of endogenous LC3 is a marker for autophagy. Autophagy. 2005;1(2):84–91.PubMed
144.
Aparicio I, et al. The autophagy-related protein LC3 is processed in stallion spermatozoa during short-and long-term storage and the related stressful conditions. Animal. 2016;10(7):1182–91.PubMed
145.
Hu Z, et al. miR-29c-3p inhibits autophagy and cisplatin resistance in ovarian cancer by regulating FOXP1/ATG14 pathway. Cell Cycle. 2020;19(2):193–206.PubMed
146.
Li H, et al. MiR-374b-5p-FOXP1 feedback loop regulates cell migration, epithelial-mesenchymal transition and chemosensitivity in ovarian cancer. Biochem Biophys Res Commun. 2018;505(2):554–60.PubMed
147.
Cheng L, et al. MiR-449b-5p regulates cell proliferation, migration and radioresistance in cervical cancer by interacting with the transcription suppressor FOXP1. Eur J Pharmacol. 2019;856:172399.PubMed
148.
Qin C, et al. LncRNA TSLNC8 inhibits proliferation of breast cancer cell through the miR-214-3p/FOXP2 axis. Eur Rev Med Pharmacol Sci. 2019;23(19):8440–8.PubMed
149.
Zhang L, et al. SOX2 regulates lncRNA CCAT1/MicroRNA-185-3p/FOXP3 axis to affect the proliferation and self-renewal of cervical cancer stem cells. Nanoscale Res Lett. 2021;16(1):1–12.
150.
Zhang Q, et al. FoxP3-miR-150-5p/3p suppresses ovarian tumorigenesis via an IGF1R/IRS1 pathway feedback loop. Cell Death Dis. 2021;12(3):1–16.PubMedPubMedCentral
151.
Rothe M, et al. A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell. 1994;78(4):681–92.PubMed
152.
153.
Li N, et al. Targeting interleukin-1 receptor-associated kinase 1 for human hepatocellular carcinoma. J Exp Clin Cancer Res. 2016;35(1):1–10.
154.
Zhu J, Mohan C. Toll-like receptor signaling pathways—therapeutic opportunities. Mediators Inflamm. 2010;2010:1–7.
155.
Rhyasen GW, et al. Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome. Cancer Cell. 2013;24(1):90–104.PubMedPubMedCentral
156.
Wee ZN, et al. IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel. Nat Commun. 2015;6(1):1–16.
157.
Zhang X, et al. Expression of IRAK1 in lung cancer tissues and its clinicopathological significance: a microarray study. Int J Clin Exp Pathol. 2014;7(11):8096.PubMedPubMedCentral
158.
Liu R, et al. FOXP3 controls an miR-146/NF-κB negative feedback loop that inhibits apoptosis in breast cancer cells. Can Res. 2015;75(8):1703–13.
159.
160.
Wang N, et al. Circular RNA circMYO9B facilitates breast cancer cell proliferation and invasiveness via upregulating FOXP4 expression by sponging miR-4316. Arch Biochem Biophys. 2018;653:63–70.PubMed
161.
Yang L, et al. CircRPPH1 serves as a sponge for miR-296-5p to enhance progression of breast cancer by regulating FOXP4 expression. Am J Transl Res. 2021;13(7):7556.PubMedPubMedCentral
162.
Li Y, et al. Forkhead box Q1: a key player in the pathogenesis of tumors. Int J Oncol. 2016;49(1):51–8.PubMed
163.
Tang H, et al. Forkhead box Q1 is critical to angiogenesis and macrophage recruitment of colorectal cancer. Front Oncol. 2020;10:2561.
164.
Feuerborn A, et al. The forkhead factor FoxQ1 influences epithelial differentiation. J Cell Physiol. 2011;226(3):710–9.PubMed
165.
Qiao Y, et al. FOXQ1 regulates epithelial-mesenchymal transition in human cancers. Can Res. 2011;71(8):3076–86.
166.
Han X, et al. MicroRNA-937 inhibits the malignant phenotypes of breast cancer by directly targeting and downregulating forkhead box Q1. Onco Targets Ther. 2019;12:4813.PubMedPubMedCentral
167.
Deng X, et al. miR-202 suppresses cell proliferation by targeting FOXR2 in endometrial adenocarcinoma. Dis Markers. 2017;2017:1–8.
168.
Zhang S, et al. circCELSR1 (hsa_circ_0063809) contributes to paclitaxel resistance of ovarian cancer cells by regulating FOXR2 expression via miR-1252. Mol Ther Nucleic Acids. 2020;19:718–30.PubMed
Metadata
Title
MicroRNAs as the critical regulators of Forkhead box protein family during gynecological and breast tumor progression and metastasis
Authors
Negin Taghehchian
Malihe Lotfi
Amir Sadra Zangouei
Iman Akhlaghipour
Meysam Moghbeli
Publication date
01-12-2023
Publisher
BioMed Central
Published in
European Journal of Medical Research / Issue 1/2023
Electronic ISSN: 2047-783X
DOI
https://doi.org/10.1186/s40001-023-01329-7

Other articles of this Issue 1/2023

European Journal of Medical Research 1/2023 Go to the issue

Research

Association of weight-adjusted-waist index with non-alcoholic fatty liver disease and liver fibrosis: a cross-sectional study based on NHANES

Review

The relationship between obstructive sleep apnea and asthma severity and vice versa: a systematic review and meta-analysis

Research

Risk factors analysis and survival prediction model establishment of patients with lung adenocarcinoma based on different pyroptosis-related gene subtypes

Review

Lymph nodes primary staging of colorectal cancer in 18F-FDG PET/MRI: a systematic review and meta-analysis

Research

Performance of severity indices for admission and mortality of trauma patients in the intensive care unit: a retrospective cohort study

Research

Association between ferritin to albumin ratio and 28-day mortality in patients with sepsis: a retrospective cohort study